Vivos Therapeutics Analyst Ratings
Vivos Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | 42.86% | Ascendiant Capital | → $2.5 | Initiates Coverage On | → Buy |
| 08/13/2021 | 471.43% | Roth Capital | $11 → $10 | Maintains | Buy |
| 05/18/2021 | 528.57% | Roth Capital | $12 → $11 | Maintains | Buy |
| 01/11/2021 | 585.71% | Craig-Hallum | → $12 | Initiates Coverage On | → Buy |
| 01/05/2021 | 585.71% | Roth Capital | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 01/17/2023 | 42.86% | 上升资本 | → 2.5 美元 | 开启覆盖范围 | → 购买 |
| 08/13/2021 | 471.43% | 罗斯资本 | 11 美元 → 10 美元 | 维护 | 买 |
| 05/18/2021 | 528.57% | 罗斯资本 | 12 美元 → 11 美元 | 维护 | 买 |
| 2021 年 11 月 1 日 | 585.71% | Craig-Hallum | → 12 美元 | 开启覆盖范围 | → 购买 |
| 01/05/2021 | 585.71% | 罗斯资本 | → 12 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Vivos Therapeutics (VVOS)?
Vivos Therapeutics（VVOS）的目标价格是多少？
The latest price target for Vivos Therapeutics (NASDAQ: VVOS) was reported by Ascendiant Capital on January 17, 2023. The analyst firm set a price target for $2.50 expecting VVOS to rise to within 12 months (a possible 42.86% upside). 1 analyst firms have reported ratings in the last year.
Ascendiant Capital于2023年1月17日公布了Vivos Therapeutics（纳斯达克股票代码：VVOS）的最新目标股价。这家分析公司将目标价定为2.50美元，预计VVOS将在12个月内升至2.86％（可能上涨42.86％）。去年有1家分析公司公布了评级。
What is the most recent analyst rating for Vivos Therapeutics (VVOS)?
Vivos Therapeutics（VVOS）的最新分析师评级是多少？
The latest analyst rating for Vivos Therapeutics (NASDAQ: VVOS) was provided by Ascendiant Capital, and Vivos Therapeutics initiated their buy rating.
Vivos Therapeutics（纳斯达克股票代码：VVOS）的最新分析师评级由Ascendiant Capital提供，Vivos Therapeutics启动了买入评级
When is the next analyst rating going to be posted or updated for Vivos Therapeutics (VVOS)?
Vivos Therapeutics（VVOS）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vivos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vivos Therapeutics was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Vivos Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Vivos Therapeutics的最新评级是在2023年1月17日提交的，因此你应该预计下一个评级将在2024年1月17日左右公布。
Is the Analyst Rating Vivos Therapeutics (VVOS) correct?
分析师对Vivos Therapeutics（VVOS）的评级正确吗？
While ratings are subjective and will change, the latest Vivos Therapeutics (VVOS) rating was a initiated with a price target of $0.00 to $2.50. The current price Vivos Therapeutics (VVOS) is trading at is $1.75, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的Vivos Therapeutics（VVOS）评级是最初的，目标价为0.00美元至2.50美元。Vivos Therapeutics（VVOS）目前的交易价格为1.75美元，在分析师的预测区间内。